Login / Signup

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.

Rebekah PenningtonMonica Hernandez-AlavaStephen PudneyAllan Wailoo
Published in: PharmacoEconomics (2020)
3L and 5L lead to substantially different estimates of incremental QALYs and cost effectiveness. The direction and magnitude of the change is not consistent across case studies. Using 5L instead of 3L may lead to different reimbursement decisions. NICE will face inconsistencies in decision making if it uses 3L and 5L concurrently.
Keyphrases
  • decision making